15 November 2025 : Review article
Signaling Pathways and Therapeutic Approaches in Post-Myocardial Infarction Fibrosis
Gen Ba ABCDEF 1*, Meiqiong Chen G 1DOI: 10.12659/MSM.949030
Med Sci Monit 2025; 31:e949030
Table 2 Registered clinical evidence for therapeutic approaches in post-MI fibrosis.
| Pathway | Strategy | Item | Reference | Year |
|---|---|---|---|---|
| TGF-β1+Wnt/β-catenin | Sacubitril/Valsartan (Lcz696) | NCT06536309 | Not yet recruiting | 7/2025 |
| NCT06655480 | Not yet recruiting | 3/18/2025 | ||
| TGF-β1+AMPK | Empagliflozin | NCT06503601 | Active, not recruiting | 7/30/2023 |
| NCT06655480 | Not yet recruiting | 3/18/2025 | ||
| TGF-β1+STAT3+AMPK+NLRP3 | Exercise training | NCT04863677 | Recruiting | 5/1/2021 |
| NCT04038723 | Completed | 8/1/2015 | ||
| NCT03711539 | Recruiting | 10/18/2018 | ||
| MI – myocardial infarction; TGF-β1 – transforming growth factor-β1; AMPK – AMP-activated protein kinase; STAT – signal transducer and activator of transcription; NLRP3 – the nucleotide-binding domain, leucine-rich-repeat family, pyrin domain-containing 3. | ||||